Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

NCT05934838 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT05934838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05934838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 4, 2023
Completion date
September 30, 2031
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma